NRIX
NURIX THERAPEUTICS, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies re-entered | Q3 2024(8Q snapshot) | 7Q | $21 | $16 | -26% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $22 | $16 | -29% |
| AQR Capital Management re-entered | Q3 2024(8Q snapshot) | 7Q | $22 | $16 | -29% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $22 | $16 | -29% |
| D.E. Shaw re-entered | Q4 2024(8Q snapshot) | 6Q | $27 | $16 | -42% |
| Point72 Asset Management | Q1 2025(8Q snapshot) | 5Q | $18 | $16 | -12% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Two Sigma Investments | Q3 2024 | Q1 2026 | → $16 | -29% |
| Duquesne Family Office | Q2 2024 | Q1 2025 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Nurix Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 2, 2026 — the most recent Form 4 on file — not from today.
- Form 40001817199-26-000020Jun 2, 2026
- Form 40001446372-26-000002May 15, 2026
- Form 40001946233-26-000002May 15, 2026
- Form 40001305361-26-000002May 15, 2026
- Form 40001734422-26-000002May 15, 2026
- Form 40001730703-26-000002May 15, 2026
- Form 40001741836-26-000004May 15, 2026
- Form 40001680739-26-000010May 15, 2026
- Form 40001226675-26-000004May 15, 2026
- Form 40001817217-26-000008May 5, 2026
- Form 40001817199-26-000018May 4, 2026
- Form 40001817199-26-000016May 1, 2026
- Form 40001817217-26-000006Apr 30, 2026
- Form 40001817199-26-000014Apr 30, 2026
- Form 40001817160-26-000008Apr 30, 2026
Fundamentals
XBRL · NURIX THERAPEUTICS, INC.Annual figures sourced directly from NURIX THERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Nurix Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 8, 2026
- 8-KMaterial eventMay 15, 2026
- 10-QQuarterly reportApr 8, 2026
- 8-KMaterial eventApr 8, 2026
- DEF 14AProxy statementMar 27, 2026
- 8-KMaterial eventMar 6, 2026
- 10-KAnnual reportJan 28, 2026
- 8-KMaterial eventJan 28, 2026
- 8-KMaterial eventJan 12, 2026
- 8-KMaterial eventDec 9, 2025
- 8-KMaterial eventNov 10, 2025
- 8-KMaterial eventOct 22, 2025
- 8-KMaterial eventOct 22, 2025
- 10-QQuarterly reportOct 9, 2025
- 8-KMaterial eventOct 9, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| D.E. Shaw | Q2 2026 | open | $16 | $16 | -2% |
| AQR Capital Management | Q2 2026 | open | $16 | $16 | -2% |
| Renaissance Technologies | Q2 2026 | open | $16 | $16 | -3% |
| Renaissance Technologies | Q2 2025 | Q1 2026 | $9.58 | $16 | +64% |
| Point72 Asset Management | Q1 2025 | open | $18 | $16 | -12% |
| D.E. Shaw | Q4 2024 | Q3 2025 | $27 | $11 | -61% |
| Citadel Advisors | Q3 2024 | open | $22 | $16 | -29% |
| Two Sigma Investments | Q3 2024 | Q1 2026 | $22 | $16 | -29% |
| AQR Capital Management | Q3 2024 | Q3 2025 | $22 | $11 | -52% |
| Millennium Management | Q3 2024 | open | $22 | $16 | -29% |
| Renaissance Technologies | Q3 2024 | Q1 2025 | $21 | $18 | -16% |
| Duquesne Family Office | Q2 2024 | Q1 2025 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.